<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01259934</url>
  </required_header>
  <id_info>
    <org_study_id>Nordic-IFN-melanoma trial</org_study_id>
    <nct_id>NCT01259934</nct_id>
  </id_info>
  <brief_title>Nordic Adjuvant IFN Melanoma Trial</brief_title>
  <official_title>Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of giving adjuvant treatment with
      intermediate doses of interferon-alpha2b to patients operated for high risk melanoma.
      Patients are randomly assigned to either observation only or interferon treatment for 2
      different durations. The outcome with respect to overall survival, relapse-free survival,
      side effects and quality of life is analysed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open multicenter, prospective randomised phase III trial evaluating the efficacy
      of two different schedules of Interferon-alpha2b (IFN-alpha2b) administered in an adjuvant
      setting after adequate surgery in high risk cutaneous melanoma patients (T4N0M0/TxN1-2M0).
      The patients have been operated for either a thick primary melanoma (&gt; 4 mm) without evidence
      of distant metastasis or have undergone surgery for regional lymph node metastases.

      The study consists of a control arm (A) and two treatment arms, B and C. The outcome in arms
      B and C with adjuvant treatment with IFN-alpha2b will be compared to the outcome of arm A in
      which the patients will only be observed after the surgery. The primary endpoint is overall
      survival. Secondary endpoints are relapse-free survival, safety-toxicity and health-related
      quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1996</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Evaluated at regular intervals: every 3 months for 2 years, every 6 months up to 5 years and yearly up to 10 years following randomization. Actual median follow-up is 72.4 months</time_frame>
    <description>All registered deaths, not only melanoma-specific.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>Evaluated at regular intervals</time_frame>
    <description>Time from randomization to date of first reported melanoma recurrence or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety-toxicity</measure>
    <time_frame>Regular evaluations</time_frame>
    <description>All toxicities and SAEs are recorded and classified according to CTC v2.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Regular evaluations</time_frame>
    <description>Recorded by using the EORTC QLQ-C30 questionnaire at nine time points during treatment and follow-up</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">855</enrollment>
  <condition>Melanoma</condition>
  <condition>Adjuvant Therapy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation only - no therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Interferon 1 year</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon Therapy: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C Interferon 2 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Two year arm&quot; Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alpha2b - 1 year</intervention_name>
    <description>Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months</description>
    <arm_group_label>Arm B Interferon 1 year</arm_group_label>
    <other_name>Intron-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alpha2b - 2 years</intervention_name>
    <description>Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months</description>
    <arm_group_label>Arm C Interferon 2 years</arm_group_label>
    <other_name>Intron-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T4 N0 M0 - Thick primary melanoma: &gt; 4.0 mm Breslow depth, without lymph node
             involvement, or

          -  Tx N1-2 M0 Primary melanoma of any thickness with regional lymph node metastases
             confirmed by lymphadenectomy, or

          -  Tx N1-2 M0 Recurrent melanoma in regional lymph node(s) confirmed by lymphadenectomy.

          -  ECOG performance status of 0-1

          -  No active medical or psychiatric disorder requiring therapy that would prevent
             completion of protocol

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with unknown primary site of melanoma or primary melanoma originating apart
             from the skin, except subungual melanoma

          -  Patients who have clinical, radiological/laboratory or pathological evidence of
             incompletely resected melanoma or distant metastatic disease

          -  Patients who have had prior adjuvant radiotherapy, chemotherapy, immunotherapy
             including preoperative infusion or perfusion therapy

          -  Female patients who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Hansson, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steinar Aamdal, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Bastholt, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital, Odense, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Micaela Hernberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Helsinki, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrika Stierner, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans von der Maase, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital, Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet, Karolinska University Hospital,</name>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Sal√®s F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. doi: 10.1093/jnci/djp132. Epub 2009 Jun 9.</citation>
    <PMID>19509353</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2010</study_first_posted>
  <last_update_submitted>December 13, 2010</last_update_submitted>
  <last_update_submitted_qc>December 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Johan Hansson, PI</name_title>
    <organization>Department of Oncology-Pathology, Karolinska Institutet</organization>
  </responsible_party>
  <keyword>Randomized Phase III trial</keyword>
  <keyword>Adjuvant therapy</keyword>
  <keyword>Interferon</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

